Skip to main content

News

Back to news
Deal announcement

ABG Sundal Collier acted as joint global coordinator and joint bookrunner in the NOK 425m IPO of BerGenBio

ABG Sundal Collier acted as joint global coordinator and joint bookrunner in the NOK 425m IPO of BerGenBio


BerGenBio ASA (”BerGenBio”) today announced the successful completion of its initial public offering (the “Offering”) and starts trading on Oslo Børs from 7 April. The Offering consisted of 16,000,000 new shares. In addition an additional 1,000,000 shares were over-allotted. The price in the Offering was NOK 25 per share, corresponding to a market value of BerGenBio after the Offering of NOK 1,244 million.

 

About BerGenBio

BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the central role of Axl kinase in promoting cancer spread, immune evasion and drug resistance in multiple aggressive hematological and solid cancers.

 

BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in Phase II clinical development in three major cancer indications. It is the only selective Axl inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer (NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast cancer (TNBC) in collaboration with Merck & Co. Inc. (MSD).

 

The Company is also developing a diversified pre-clinical pipeline of selective Axl inhibitors including BGB149, anti-Axl monoclonal antibody.